Skip to content
Menu

Rani Therapeutics Hldgs Q3 EPS $(0.04) Beats $(0.05) Estimate, Sales $1.707M Beat $1.280M Estimate

Benzinga Newsdesk 1 week ago

NewsEarningsEarnings Beats

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. This is a 66.67 percent increase over losses of $(0.12) per share

Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. This is a 66.67 percent increase over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $1.707 million which beat the analyst consensus estimate of $1.280 million by 33.41 percent.

Read at benzinga.com